Visceral pain

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

Retrieved on: 
Thursday, April 11, 2024
Irritable bowel syndrome, University, System, UNC, Research, NYU, Entrepreneurship, Visceral pain, Therapy, Patient, CSO, DDW, Annual general meeting, Abdominal pain, IBS, Pharmaceutical industry

REHOVOT, Israel, April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting.

Key Points: 
  • REHOVOT, Israel, April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting.
  • The conference is being held in Washington, D.C., May 18-21, 2024.
  • The pre-clinical work was led by Prof. Yehuda Ringel, Biomica's Co-Founder and CSO, in collaboration with the lab of Prof. Kara Gross Margolis, at the NYU Grossman School of Medicine.
  • In the studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427.

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Thursday, March 21, 2024
Ulcerative colitis, GPR35, Partnership, GSK, Research, Health care, Irritable bowel syndrome, Visceral pain, IBD, Therapy, Safety, Inflammatory Bowel Diseases, Pharmaceutical industry

HTL0027477 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.

Key Points: 
  • HTL0027477 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.
  • Sosei Heptares regained full ownership of the HTL0027477 program including associated intellectual property licensed by Sosei Heptares to GSK, and preclinical data generated under the partnership for no upfront payment.
  • Sosei Heptares expects to determine the optimal strategy for further clinical development of the program, which could include in-house development and re-partnering.
  • This presents a clear opportunity for Sosei Heptares to further advance this program while determining the optimal path forward for further development and commercialization.”

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Shekel, Growth, Sale, Perception, Health, Webcast, Fruit, Herbicide, AG, Generator, CFIA, Marketing, Seed, Canadian Food Inspection Agency, CPB, Therapy, Production, ICL, Burn, Conference, Safety, Collaboration, Patent, CO2, Agreement, Insurance, Visceral pain, Agricultural science, Gene editing, EIC, Probiotic, Computational biology, Patient, Israeli new shekel, IBS, Pharmaceutical industry

REHOVOT, Israel, March 7, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Key Points: 
  • Collaboration with Colors Farm and Ben Gurion University: Evogene partnered to pioneer crustacean gene editing technology aimed at enhancing crustacean traits.
  • EU Grant for Ag-Seed Division: Evogene secured a €1.2 million EU grant to develop oil-seed crops with enhanced CO2 assimilation and drought tolerance.
  • In the fourth quarter of 2023, general and administrative expenses were approximately $1.2 million, down from about $1.7 million in the same period the previous year.
  • This increase in net loss during the fourth quarter of 2023 is primarily attributed to other income received in 2022, as mentioned above.

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Friday, November 24, 2023
IBD, Partnership, Research, Acquisition, GSK, Visceral pain, Inflammatory Bowel Diseases, Irritable bowel syndrome, Safety, GPR35, Ulcerative colitis, Pharmaceutical industry

GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.

Key Points: 
  • GSK4381406 was designed by Sosei Heptares using its proprietary structure-based drug design (SBDD) platform and licensed to GSK in 2020.
  • GSK becomes eligible for a low single digit royalty from Sosei Heptares on net sales of GSK4381406 should it become commercially available.
  • Sosei Heptares’ strategy is to advance novel or best-in-class products through early clinical development before seeking a partner to develop and commercialize in major markets.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “We are delighted at the prospect of regaining ownership of GSK4381406 from GSK.

Evogene Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 17, 2023
Shekel, Computational biology, Operating cost, Therapy, Irritable bowel syndrome, Seed, Marketing, Renal cell carcinoma, Farmer, Non-small-cell lung cancer, Canadian Food Inspection Agency, Clinical trial, Rambam Health Care Campus, Generator, CFIA, Fruit, Irritation, Conference call, Protein, Pesticide, International use of the U.S. dollar, Patient, IBS, Melanoma, Algorithm, TASE, AG, Visceral pain, Webcast, BMS, Conference, Safety, Automation, Pharmaceutical industry, Cryptocurrency, Video game, Broadcasting, New York University, Corteva, Evogene, Canonical

REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.

Key Points: 
  • REHOVOT, Israel, Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.
  • Ofer Haviv, Evogene's President and Chief Executive Officer, stated: "The second quarter of 2023 marked a period of remarkable achievements for the Evogene group.
  • Revenues for the second quarter of 2023 were approximately $654 thousand compared to approximately $312 thousand in the same period the previous year.
  • This difference was mainly due to the U.S. Dollar and Shekel exchange rate differences between periods, a decrease in marketable securities value in the second quarter of 2022 and an increase in interest income during the second quarter of 2023.

Fzata Raising Series A For New Oral Biologics Platform Modality

Retrieved on: 
Thursday, January 26, 2023
Inflammation, Clostridioides difficile, Inflammatory Bowel Diseases, SEED, Therapy, Diabetes, Clostridioides difficile infection, NIH, BIO, Visceral pain, Ulcerative colitis, Pharmaceutical industry, IND

HALETHORPE, Md., Jan. 26, 2023 /PRNewswire/ -- Fzata, Inc., announces that it is raising series A funding for its first-in-class Bioengineered Probiotic Yeast Medicines (BioPYM™) platform.

Key Points: 
  • HALETHORPE, Md., Jan. 26, 2023 /PRNewswire/ -- Fzata, Inc., announces that it is raising series A funding for its first-in-class Bioengineered Probiotic Yeast Medicines (BioPYM™) platform.
  • This is a novel oral administration modality for biologics.
  • Fzata's vision is to replace needle administration of biologics with a capsule for suffers of gastrointestinal disorders.
  • Dr. Zhiyong Yang, President and CEO of Fzata, commented: "Fzata has been honored to be a SEED company with the NIH.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Gastroesophageal reflux disease, Constipation, United States Air Force Scientific Advisory Board, Indigestion, The American Journal of Gastroenterology, Gastroparesis, Intestinal pseudo-obstruction, Lacy, Rome, Stomach, Mayo Clinic, IBS, Visceral pain, Gastrointestinal tract, Textbook, Patient, Diet, Research, Irritable bowel syndrome, Clinical and Translational Gastroenterology, Science, Book, Dysphagia, Esophageal achalasia, Esophageal motility disorder, Physician, American Journal, Medical device, Pharmaceutical industry, Gastroenterology

Dr. Lacy has authored over 225 peer reviewed articles

Key Points: 
  • Dr. Lacy has authored over 225 peer reviewed articles
    IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product.
  • I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”
    Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain.
  • Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.
  • “Dr.

Fzata to Pitch BioPYM™ Platform at the Biotech Showcase™ 2023

Retrieved on: 
Tuesday, December 20, 2022
Needle, CDI, Diabetes, Obesity and Metabolism, Inflammatory Bowel Diseases, Investment, IBD, Diabetes, Conference, Inflammation, Ulcerative colitis, Clostridioides difficile infection, IND, Therapy, Degenerative disease, Visceral pain, Infection, Research, Cancer, NIH, Pharmaceutical industry, MD

Fzata will pitch live Wednesday, January 11 at 4:15, Room Franciscan B, Hilton San Francisco Union Square.

Key Points: 
  • Fzata will pitch live Wednesday, January 11 at 4:15, Room Franciscan B, Hilton San Francisco Union Square.
  • Fzata will also attend the virtual event January 18-19, 2023.
  • Dr. Zhiyong Yang, President and CEO of Fzata, commented, "Our vision is to expand patient access to therapeutic biologics.
  • About Fzata, Inc.: Fzata ( www.Fzata.com ) is a near-clinical stage biopharmaceutical company, developing oral live biologic-based preventive and therapeutic medicines.

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

Retrieved on: 
Wednesday, May 25, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, University of Oklahoma Health Sciences Center, University of Leuven, Pain, Disease, Constipation, IC/BPS, Abdominal pain, DDW, Bloating, Nasdaq, Patient, Gastrointestinal disease, IBS-C, Endometriosis, Early Life Stage test, Clinical trial, CIC, White, Research, GC, Guanosine monophosphate, Medication, Human, Stanford University Medical Center, Quality of life, Ironwood Pharmaceuticals, University, GC-C, Pain scale, Sensation, AS, Irritable bowel syndrome, Functional constipation, Visceral pain, Pharmaceutical industry, Ironwood

Ironwood is currently developing IW-3300, a guanylate cyclase-c (GC-C) agonist, for the potential treatment of visceral pain conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis.

Key Points: 
  • Ironwood is currently developing IW-3300, a guanylate cyclase-c (GC-C) agonist, for the potential treatment of visceral pain conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis.
  • These results are exciting because they show the potential of IW-3300 to relieve visceral pain via a neuronal cross-talk mechanism mediated by the GC-C pathway.
  • Both trials evaluated meaningful changes from baseline to week 12 in Abdominal Score (AS), a composite of abdominal pain, bloating and discomfort.
  • Ironwood is currently advancing IW-3300, a guanylate cyclase-C agonist being developed for the potential treatment of visceral pain conditions, such as interstitial cystitis / bladder pain syndrome (IC/BPS) and endometriosis.

P2X Purinoceptor 3 (P2RX3) - Global Therapeutic Landscape Assessment, 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 16, 2022
Health, Pharmaceutical, Visceral pain, Health, P2RX3, Neuropathic pain, R, Pre-registration house officer, Alzheimer's disease, Target, Central nervous system, Low back pain, Disease, Therapy, Obstructive sleep apnea, Women's health, ROA, Mall of America, Ocular hypertension, Neuralgia, Discovery, Overactive bladder, Fine chemical, Itch, P2X, Cough, Pain, Insomnia, Ophthalmology, Dermatology, Endometriosis

The "P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules.
  • The report outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.